Trial Profile
Safety Study of Olpatadine Nasal Spray.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Olopatadine (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alcon
- 05 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2008 New trial record.